So far, the FDA has primarily approved treatments for AD that focus on compensating for cholinergic neuron loss using drugs such as inhibitors for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), including medications like tacrine, donepezil, rivastigmine, and galantamine, as well as the glutamatergic drug memantine, which functions as an N-methyl-D-aspartate (NMDA) receptor antagonist (Albertini et al. 2021). This evidence concerns the gene BCHE and Alzheimer disease.